Viatris Brands — Finite-lived intangible assets, net decreased by 10.7% to $13.11B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 10.7%, from $14.69B to $13.11B.
A steady decrease is expected due to amortization, while a sharp decline may signal asset impairment; an increase typically follows new acquisitions of product portfolios.
This metric represents the net book value of identifiable intangible assets associated with branded products that have a...
Comparable to 'Net Intangible Assets' or 'Product Rights' reported by other pharmaceutical firms, often analyzed relative to the remaining useful life of the portfolio.
vtrs_segment_brands_finite_lived_intangible_assets_net| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $21.15B | $18.58B | $16.75B | $14.69B | $13.11B |
| QoQ Change | — | -12.1% | -9.9% | -12.3% | -10.7% |
| YoY Change | — | -12.1% | -9.9% | -12.3% | -10.7% |